<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2006-12-3-194-199</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-1066</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Сравнительная эффективность нифедипина длительного действия и атенолола в коррекции поражений органов-мишеней у больных гипертонической болезнью</article-title><trans-title-group xml:lang="en"><trans-title>Comparative efficacy of nifedipine-retard and atenolol in correction of target organ damage in patients with essential hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Емельянов</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Emelyanov</surname><given-names>I. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виллевальде</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Villevalde</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лясникова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyasnikova</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеева</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseeva</surname><given-names>O. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГУ НИИ кардиологии имени В.А.Алмазова Росздрава</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2006</year></pub-date><volume>12</volume><issue>3</issue><fpage>194</fpage><lpage>199</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Емельянов И.В., Виллевальде С.В., Лясникова Е.А., Моисеева О.М., 2006</copyright-statement><copyright-year>2006</copyright-year><copyright-holder xml:lang="ru">Емельянов И.В., Виллевальде С.В., Лясникова Е.А., Моисеева О.М.</copyright-holder><copyright-holder xml:lang="en">Emelyanov I.V., Villevalde S.V., Lyasnikova E.A., Moiseeva O.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/1066">https://htn.almazovcentre.ru/jour/article/view/1066</self-uri><abstract><p>Целью настоящего исследования являлась оценка связи между гипотензивным эффектом монотерапии корди-пином XL и атенололом и динамикой показателей, характеризующих поражение органов-мишеней: сердца и магистральных артерий, а также функцию эндотелия у больных ГБ II стадии. В открытое проспективное сравнительное исследование было включено 45 больных ГБ II стадии: 24 пациента в группу терапии нифедипином в дозе 40 мг в день и 21 пациент в группу терапии атенололом в дозе 50-100 мг в день. Больные обеих групп были сопоставимы по основным клиническим и гемодинамическим параметрам. Суточное мониторирование АД, эхокардиографическое исследование и оценка эдотелийзависимой и эндотелийнезависимой вазодилатации проводились перед включением пациентов в исследование (после 14 дней периода «отмывания») и в конце 6-месячного периода лечения. При монотерапии в течение 6 месяцев больных ГБ II стадии кордипин XL и атенолол оказывают сопоставимое и значимое антигипертензивное действие. На фоне длительного лечения нифедипином-ретард, в отличие от терапии атенололом, отмечен не только регресс гипертрофии левого желудочка (ГЛЖ), но и улучшение диастолической функции ЛЖ, причем это касалось как параметров активного, так и пассивного расслабления ЛЖ. Длительная терапия кордипином XL, ассоциируясь с увеличением объемной скорости кровотока по лучевой артерии при ГБ, приводит к коррекции эндотелиальной дисфункции, как одного из ключевых звеньев сердечно-сосудистого континуума. </p></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to assess the relationship between antihypertensive effect of nifedipine-retard and atenolol long-term therapy and changes of target organ damage (heart, carotid arteries, endothelial function) in patients with essential hypertension (HT) 2 stage. 45 patients with AH were included in the open prospective randomized study: 24 received nifedipine-retard 40 mg per day, 21 received atenolol 50 - 100 mg per day. There were no clinical and haemodynamic discrepanses between the groups at basline. Ambulatory blood pressure monitoring (ABPM), echocardiography (EchoCG), assess of endothelium-dependent and endothelium-independent vasodilatation were performed at basal state (after 14 days wash-out period) and after 6-month therapy. Both nifedipine-retard and atenolol had comparable and apparent hypotensive effect. The regression of left ventricular hypertrophy and the improvement of left ventricle diastolic function became evident during nifedipine-retard therapy in contrast to atenolol treatment. Long-term nifedipine-retard therapy is accompanied by an increase of volume flow velocity in arteria radialis and leads to correction of endothelium dysfunction in patients with HT. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>антигипертензивпая терапия</kwd><kwd>артериальная гипертензия</kwd><kwd>артериальное давление</kwd><kwd>атенолол</kwd><kwd>гипертрофия левого желудочка</kwd><kwd>дисфункция эндотелия</kwd><kwd>нифедипин</kwd><kwd>поражения органов-мишеней</kwd></kwd-group><kwd-group xml:lang="en"><kwd>antihypertensive therapy</kwd><kwd>arterial hypertension</kwd><kwd>atenolol</kwd><kwd>blood pressure</kwd><kwd>endothelial dysfunction</kwd><kwd>left ventricle hypertrophy</kwd><kwd>nifedipine</kwd><kwd>target organ damage</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">European Society of Hypertension - European Society of Cardiology Guidelines for the management of arterial Hypertension. Guidelines Committее. J Hypertens 2003; 21: 1011-53.</mixed-citation><mixed-citation xml:lang="en">European Society of Hypertension - European Society of Cardiology Guidelines for the management of arterial Hypertension. Guidelines Committее. J Hypertens 2003; 21: 1011-53.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Всероссийское научное общество кардиологов (ВНОК). Национальные рекомендациипо диагностике и лечению артериальной гипертонии. М., 2004</mixed-citation><mixed-citation xml:lang="en">Всероссийское научное общество кардиологов (ВНОК). Национальные рекомендациипо диагностике и лечению артериальной гипертонии. М., 2004</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.</mixed-citation><mixed-citation xml:lang="en">Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Borhani N.O., Mercuri M., Borhani P. et al. Final outcome results of the multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS).JAМA 1996;276:785-91.</mixed-citation><mixed-citation xml:lang="en">Borhani N.O., Mercuri M., Borhani P. et al. Final outcome results of the multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS).JAМA 1996;276:785-91.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Omae T., Matsuoka H., Arakawa K. et al. A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension. Hypertens Res 1995;18:235-44.</mixed-citation><mixed-citation xml:lang="en">Omae T., Matsuoka H., Arakawa K. et al. A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension. Hypertens Res 1995;18:235-44.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Psaty B.M., Heckbert S.R., Koepsell T.D. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-5.</mixed-citation><mixed-citation xml:lang="en">Psaty B.M., Heckbert S.R., Koepsell T.D. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-5.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Aldermen M.N., Cohen H., Rogue R., Madhevan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997:349:594-8.</mixed-citation><mixed-citation xml:lang="en">Aldermen M.N., Cohen H., Rogue R., Madhevan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997:349:594-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">The ALLHAT Officers and Coordinations. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker is diuretic (ALLHAT). JAMA 2002; 288: 2981-97.</mixed-citation><mixed-citation xml:lang="en">The ALLHAT Officers and Coordinations. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker is diuretic (ALLHAT). JAMA 2002; 288: 2981-97.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.</mixed-citation><mixed-citation xml:lang="en">Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Staessen J., Ji-Guang Wang, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15: 85S-93S.</mixed-citation><mixed-citation xml:lang="en">Staessen J., Ji-Guang Wang, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15: 85S-93S.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Stason W.B., Schmid C.H., Niedzwiecki D. et al. Safety of nifedipine in patients with hypertension. A mcta-analysis. Hypertension 1997; 30: 7-14.</mixed-citation><mixed-citation xml:lang="en">Stason W.B., Schmid C.H., Niedzwiecki D. et al. Safety of nifedipine in patients with hypertension. A mcta-analysis. Hypertension 1997; 30: 7-14.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mac Mahon N.B., Cauinan S. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. BPLTCT. Lancet 2004; 345:1076-78</mixed-citation><mixed-citation xml:lang="en">Mac Mahon N.B., Cauinan S. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. BPLTCT. Lancet 2004; 345:1076-78</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Brown M., Palmer C., Castaigne L. et al. Morbidity and Mortality in Patients Randomized to Double-Blind Treatment with Long-Acting Calcium Channel Blockers or Diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000, 356: 366-72.</mixed-citation><mixed-citation xml:lang="en">Brown M., Palmer C., Castaigne L. et al. Morbidity and Mortality in Patients Randomized to Double-Blind Treatment with Long-Acting Calcium Channel Blockers or Diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000, 356: 366-72.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Agabiti-Rosei E., Zulli R., Muiesan M. et al. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. Blood Pressure, 1998; 7(3): 160-9.</mixed-citation><mixed-citation xml:lang="en">Agabiti-Rosei E., Zulli R., Muiesan M. et al. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. Blood Pressure, 1998; 7(3): 160-9.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Staessen J.A., Fagard R., Thijs L. et al., for the Systolic Hypertension in Europe Trial Investigators. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.</mixed-citation><mixed-citation xml:lang="en">Staessen J.A., Fagard R., Thijs L. et al., for the Systolic Hypertension in Europe Trial Investigators. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lindhohn L.H., Hansson L., Ekbom T. et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group./Hypertens 2000 Nov; 18(11): 167.</mixed-citation><mixed-citation xml:lang="en">Lindhohn L.H., Hansson L., Ekbom T. et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group./Hypertens 2000 Nov; 18(11): 167.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zanchetti A., Bond G., Hennig M. et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of European Lacidipine Study of Atherosclerosis (ELSA): a randomized, double-blind, long-term trail. Circulation 2002; 106: 2422-2426.</mixed-citation><mixed-citation xml:lang="en">Zanchetti A., Bond G., Hennig M. et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of European Lacidipine Study of Atherosclerosis (ELSA): a randomized, double-blind, long-term trail. Circulation 2002; 106: 2422-2426.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pitt B., Byington R.P., Furberg C.D. et al. Effect of amlodipin on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.</mixed-citation><mixed-citation xml:lang="en">Pitt B., Byington R.P., Furberg C.D. et al. Effect of amlodipin on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Simon A., Gariepy J., Moyse D., Levenson J. Differential effects of nifedipine and coamilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949-2954.</mixed-citation><mixed-citation xml:lang="en">Simon A., Gariepy J., Moyse D., Levenson J. Differential effects of nifedipine and coamilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949-2954.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">ENCORE Investigators/Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003', 107 (3): 422-8.</mixed-citation><mixed-citation xml:lang="en">ENCORE Investigators/Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003', 107 (3): 422-8.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Virdis A., Taddei S. et al. Nifedipine improves endothelium-dependent vasodilatation by restoring nitric oxide. Am J Hypertens 1999-, 12 (Suppl.): 57A.</mixed-citation><mixed-citation xml:lang="en">Virdis A., Taddei S. et al. Nifedipine improves endothelium-dependent vasodilatation by restoring nitric oxide. Am J Hypertens 1999-, 12 (Suppl.): 57A.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
